Radiopharm RAD 101 meets Phase 2b endpoint in brain metastases

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. CSX
6. LRCX
7. LVS
8. SAP
9. SPCX
10. SPY

Go back to Radiopharm RAD 101 meets Phase 2b endpoint in brain metastases

Radiopharm Theranostics Reports Business Update

July 31, 2026 7:00 AM EDT

Reported positive results from the Phase 2b clinical trial of imaging agent RAD 101, showing 93% of evaluable patients treated with RAD 101 achieved the primary endpoint 

Plans to initiate Phase 3 registrational trial of RAD 101 in Q4 2026

Raised approximately $12.5M through an institutional offer and launched a $6million Share Purchase Plan, post balance date

SYDNEY, July 31, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, Radiopharm or the Company), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced... More